Form 8-K Summary
Registrant: Blue Water Vaccines Inc. (the request metadata identifies Onconetix, Inc.; the filing itself names Blue Water Vaccines Inc.)
Report date: October 9, 2022; signed October 12, 2022. This is a current report under Sections 13 or 15(d) of the Exchange Act and does not report quarterly or annual financial results.
Business Context and Reporting Period
The company furnished an investor presentation as Exhibit 99.1 for meetings planned at the World Vaccine Congress in Barcelona on October 13, 2022. The presentation was furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other filings.
Key Financial and Operating Information
- No revenue, earnings, cash flow, margin, debt, liquidity, or balance-sheet figures are provided in the filing text.
- The company agreed to pay Boustead Securities, LLC a $1.0 million cash fee plus $50,000 of legal expenses.
- The company also agreed to issue Boustead 93,466 restricted common shares in exchange for cancellation of Boustead’s February 23, 2022 representative warrant.
Material Changes and Unusual Items
On October 9, 2022, the company entered into a settlement agreement and release with Boustead, effective September 28, 2022. The dispute arose from the company’s February 2022 initial public offering and alleged breaches relating to Boustead’s right of first refusal and a standstill provision.
Under the settlement, Boustead waived its right of first refusal and the standstill restriction and released certain claims concerning the April 2022 private placement, the August 2022 private placement, and future private, public equity, or debt offerings. The company also released Boustead from claims, subject to stated exceptions.
Outlook, Risks, and Contingencies
- The settlement removes specified restrictions that could otherwise have affected the company’s financing activities before February 17, 2023.
- The cash payment and share issuance represent material settlement consideration and may affect cash resources and share dilution; the filing does not provide the company’s resulting liquidity position or the terms and valuation of the cancelled warrant.
- The filing does not provide formal financial guidance or detailed management outlook.
Investor Verification Items
- Confirm the registrant’s identity, because the filing names Blue Water Vaccines Inc., while the request metadata names Onconetix, Inc.
- Review Exhibit 99.1 for the company’s presentation and any operating or pipeline updates.
- Verify payment of the $1.05 million aggregate cash consideration and issuance of the 93,466 restricted shares.
- Review subsequent filings for the settlement’s accounting treatment, dilution impact, and any additional financing activity.
- Confirm the scope of the releases, exceptions, and any remaining claims or obligations under the settlement agreement.